Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
214.00
+5.00 (2.39%)
Jul 10, 2025, 1:30 PM CST
-29.26%
Market Cap 56.01B
Revenue (ttm) 19.12B
Net Income (ttm) 5.46B
Shares Out 261.75M
EPS (ttm) 20.73
PE Ratio 10.32
Forward PE 10.73
Dividend 5.73 (2.74%)
Ex-Dividend Date Aug 5, 2024
Volume 1,282,947
Average Volume 951,378
Open 209.50
Previous Close 209.00
Day's Range 209.00 - 215.50
52-Week Range 172.50 - 307.50
Beta -0.06
RSI 41.77
Earnings Date Aug 7, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business... [Read more]

Sector Healthcare
Founded 1966
Employees 1,099
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1795
Full Company Profile

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.

Financial Statements

News

There is no news available yet.